לא מצאתי מאמרים על בעיות עם פבוקסיל בזמן ההנקה בלבד)
Rev Neurol 2003 Apr 16-30;36(8):724-6 Related Articles, Links
[Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine]
[Article in Spanish]
Salvia Roiges MD, Garcia L, Gonce Mellgren A, Esque Ruiz MT, Figueras Aloy J, Carbonell Estrany X.
Institut Clinic d Obstetricia, Ginecologia i Neonatologia (ICGON), Barcelona, Espa a.
INTRODUCTION. Selective serotonin reuptake inhibitors (SSRIs) are often used as antidepressants in pregnant women. SSRIs do not appear to increase the teratogenic risk when used in their recommended doses. However, not enough information is available at this time about the risk of toxicity and complications in newborns, after mother treatment with SSRI during the third trimester of pregnancy. We are limited to the existing reports that describe newborns with symptoms due to hyperserotoninemia or withdrawal. CASE REPORT. One newborn whose mother had been treated with paroxetine 20 mg/day during pregnancy, presented convulsions and subarachnoid haemorrhage in the first six hours of life. The newborn did not present symptoms of hypoxic ischaemic encephalopathy, withdrawal syndrome, infection, metabolic alterations, cerebral malformations or coagulopaties. DISCUSSION. The most probable etiology is that the paroxetine could decrease the seizure threshold, taking place the first seizure during delivery. The difficult fetal extraction would have provoked the subarachnoid haemorrhage in a patient with an impaired haemostatic function due to a depletion of platelet serotonin and may also contribute the increased vascular fragility due to paroxetine and reported in adults or in animals. CONCLUSION. Neonatal convulsions and subarachnoid haemorrhage may occur after paroxetine treatment in the third trimester of pregnancy. An accurate follow up of these newborns in the firsts days of life is strongly recommended.
PMID: 12717649 [PubMed - in process]
Rev Neurol 2003 Apr 16-30;36(8):724-6 Related Articles, Links
[Neonatal convulsions and subarachnoid hemorrhage after in utero exposure to paroxetine]
[Article in Spanish]
Salvia Roiges MD, Garcia L, Gonce Mellgren A, Esque Ruiz MT, Figueras Aloy J, Carbonell Estrany X.
Institut Clinic d Obstetricia, Ginecologia i Neonatologia (ICGON), Barcelona, Espa a.
INTRODUCTION. Selective serotonin reuptake inhibitors (SSRIs) are often used as antidepressants in pregnant women. SSRIs do not appear to increase the teratogenic risk when used in their recommended doses. However, not enough information is available at this time about the risk of toxicity and complications in newborns, after mother treatment with SSRI during the third trimester of pregnancy. We are limited to the existing reports that describe newborns with symptoms due to hyperserotoninemia or withdrawal. CASE REPORT. One newborn whose mother had been treated with paroxetine 20 mg/day during pregnancy, presented convulsions and subarachnoid haemorrhage in the first six hours of life. The newborn did not present symptoms of hypoxic ischaemic encephalopathy, withdrawal syndrome, infection, metabolic alterations, cerebral malformations or coagulopaties. DISCUSSION. The most probable etiology is that the paroxetine could decrease the seizure threshold, taking place the first seizure during delivery. The difficult fetal extraction would have provoked the subarachnoid haemorrhage in a patient with an impaired haemostatic function due to a depletion of platelet serotonin and may also contribute the increased vascular fragility due to paroxetine and reported in adults or in animals. CONCLUSION. Neonatal convulsions and subarachnoid haemorrhage may occur after paroxetine treatment in the third trimester of pregnancy. An accurate follow up of these newborns in the firsts days of life is strongly recommended.
PMID: 12717649 [PubMed - in process]
ועוד אחד לא מוצא בעיות:
Am J Obstet Gynecol 2003 Mar;188(3):812-5 Related Articles, Links
Birth outcomes after prenatal exposure to antidepressant medication.
Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L.
UCLA Neuropsychiatric Institute and Hospital, Los Angeles, Calif, USA. vhendric@ucla.edu
OBJECTIVE: The purpose of this study was to examine prospectively the incidence of congenital anomalies and neonatal complications after prenatal exposure to antidepressant medication. STUDY DESIGN: Birth outcomes were obtained from a review of obstetric and neonatal records of 138 women who were treated with selective serotonin reuptake inhibitor antidepressant medications (SSRIs) during pregnancy. RESULTS: The incidence of congenital anomalies in this study was 1.4%, comparable to general population rates. Rates of low birth weight and preterm births were low, occurring in 2.9% and 6.5% of births, respectively. The low birth weight infants had been exposed to relatively high doses of fluoxetine (40-80 mg/d) throughout pregnancy. Average maternal weight gain in pregnancy was comparable across the three major medication categories (fluoxetine, paroxetine, sertraline). CONCLUSION: After prenatal use of selective serotonin reuptake inhibitor antidepressant medications, neonatal complications and congenital anomalies appear to occur within general population rates. However, maternal use of high doses of fluoxetine throughout pregnancy may be associated with a risk for low birth weight.
PMID: 12634662 [PubMed - indexed for MEDLINE]
|
תוכן התגובה:
|
